Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2025 February Clinical trials Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL Read more
2025 February Clinical trials Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukaemia Read more
2025 January Clinical trials 131I-Apamistamab before alloHCT for older patients with R/R AML Read more
2025 January Clinical trials Transfusion independence with luspatercept in ESA-naive patients with lower-risk MDS Read more
Top
